TREATING AND CURING COVID-19 INFECTION UTILIZING A LASER
An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a virion in the body fluid to form an antibody-virion complex, wherein the antibody comprises a tag sensitive to an illumination; removing the antibody-virion complex from the body fluid using an illumination source; and returning the body fluid to the patient. Other aspects are described and claimed.
1 . A method for treating a body fluid of a patient with Covid-19, comprising:
removing the body fluid from a patient;
applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a virion in the body fluid to form an antibody-virion complex, wherein the antibody comprises a tag sensitive to an illumination;
removing the antibody-virion complex from the body fluid using an illumination source; and
returning the body fluid to the patient.
2 . The method of claim 1 , wherein the antibody comprises an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 2 and a VL domain having the amino acid sequence of SEQ ID. No. 4.
3 . The method of claim 1 , wherein the antibody comprises an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 6 and a VL domain having the amino acid sequence of SEQ ID. No. 8.
4 . The method of claim 1 , wherein the tag is selected from the group consisting of: a fluorescent tag and a luminous tag.
5 . The method of claim 1 , wherein the illumination source comprises a narrow beam laser.
6 . The method of claim 5 , wherein the narrow beam laser is less than 10 nanometers in diameter.
7 . The method of claim 1 , wherein the illumination source annihilates the antibody-virion complex and a disease-causing potential of the virion.
8 . The method of claim 1 , further comprising determining an efficacy of treatment, using the illumination source, based on testing the body fluid after the treating the body fluid and before returning the body fluid to the patient.
9 . The method of claim 1 , wherein the removal further comprises a sensor for detecting individual antibody-virion complexes.
10 . The method of claim 1 , wherein the body fluid is selected from the group consisting of: blood and cerebrospinal fluid.
11 . A device for treating a body fluid of a patient with Covid-19, comprising:
a transparent first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber;
a transparent second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing an antibody into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the antibody can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid; and
an illumination source;
the device being configured to:
remove the body fluid from a patient;
apply a treatment to the body fluid, wherein the treatment comprises the antibody that joins with a virion in the body fluid to form an antibody-virion complex, wherein the antibody comprises a tag sensitive to an illumination;
remove the antibody-virion complex from the body fluid using an illumination source; and
return the body fluid to the patient.
12 . The device of claim 11 , wherein the antibody comprises an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 2 and a VL domain having the amino acid sequence of SEQ ID. No. 4.
13 . The device of claim 11 , wherein the antibody comprises an isolated monoclonal antibody comprising a VH domain having the amino acid sequence of SEQ. ID No. 6 and a VL domain having the amino acid sequence of SEQ ID. No. 8.
14 . The device of claim 11 , wherein the tag is selected from the group consisting of: a fluorescent tag and a luminous tag.
15 . The device of claim 11 , wherein the illumination source comprises a narrow beam laser.
16 . The device of claim 15 , wherein the narrow beam laser is less than 10 nanometers in diameter.
17 . The device of claim 11 , wherein the illumination source annihilates the antibody-virion complex and a disease-causing potential of the virion.
18 . The device of claim 11 , further comprising determining an efficacy of treatment, using the illumination source, based on testing the body fluid after the treating the body fluid and before returning the body fluid to the patient.
19 . The device of claim 11 , wherein the removal further comprises a sensor for detecting individual antibody-virion complexes.
20 . A product for treating a body fluid of a patient with Covid-19, comprising:
a transparent first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber;
a transparent second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing an antibody into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the antibody can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid; and
an illumination source.